

July 3, 1970

Dr. Wilma Harrison
Geigy Pharmaceuticals
Ardsley, New York

Dear Wilma,

As I mentioned on the phone, I have discussed the list of clinicians willing, interested and able to evaluate the antidepressant and antianxiety effects of new compounds with some of my associates and with Dr. Stephen Bernstein of the ECDEU program of NIMH. The following investigators should be considered for an evaluation of GP 41299.

Schiele and Abuzzahab:	University of Minnesota
Cole, DiMascio, Schader:	Boston State Hospital
Goldstein:	University of Miami
Rickels:	University of Pennsylvania
Merlis:	Central Islip State Hospital
Klein, D.:	Hillside Hospital

There must be others, but they do not come to mind in this review. Occasionally, Hollister (V.A., Stanford) has taken on a new compound; Sugerman has done some OPD studies at a private hospital in New Jersey; and Gallant (Tulane U.) has reported on antidepressant and antianxiety compounds in alcoholics.

I trust this is helpful. If there is anything I can do to assist in this venture, please call on me.

My best.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

mf/